Skip to main content
PMC home page
Thorax logoLink to Thorax
. 1968 Mar;23(2):187–193. doi: 10.1136/thx.23.2.187

Busulphan lung

B E Heard 1,1, R A Cooke 1,2
PMCID: PMC471775  PMID: 5240498

Abstract

Histological changes attributable to busulphan were found at necropsy in the lungs of six out of 14 cases of chronic granulocytic leukaemia. The alveoli contained persistent fibrinous oedema converting to fibrous tissue, and also atypical cells. Only one out of seven controls with leukaemia showed fibrinous oedema, and atypical cells were absent. In the lungs from rare cases of fatal pulmonary fibrosis due to busulphan, the histological changes were similar but more severe. It is concluded that busulphan commonly causes fibrinous oedema in chronic granulocytic leukaemia and on rare occasions it becomes severe or persistent enough to cause fatal fibrosis of the lungs. The name busulphan lung is suggested for any of these changes. The term `intra-alveolar fibrosis' should be used instead of `interstitial fibrosis', as it had been called by most previous authors. Despite these findings we consider that this valuable drug should be discontinued only in those very rare instances when intra-alveolar fibrosis shows signs of becoming disabling.

Full text

PDF
192

Images in this article

188Image
on p.188
189Image
on p.189
190Image
on p.190
191Image
on p.191
191Image
on p.191

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. CHEVREMONT M., BAECKELAND E., FREDERIC J. [Cytochemical and histoautoradiographic contribution to the study of the metabolism and synthesis of desoxyribonucleic acids in animal cells cultured in vitro. I. Cytophotometric and histoautoradiographic studies on desoxyribonucleic acids in myleran-treated fibroblasts]. Biochem Pharmacol. 1960 Aug;4:57–66. doi: 10.1016/0006-2952(60)90046-0. [DOI] [PubMed] [Google Scholar]
  2. DIAMOND I., ANDERSON M. M., McCREADIE S. R. Transplacental transmission of busulfan (myleran) in a mother with leukemia. Production of fetal malformation and cytomegaly. Pediatrics. 1960 Jan;25:85–90. [PubMed] [Google Scholar]
  3. DONIACH I., MORRISON B., STEINER R. E. Lung changes during hexamethonium therapy for hypertension. Br Heart J. 1954 Jan;16(1):101–108. doi: 10.1136/hrt.16.1.101. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. GALTON D. A. Myleran in chronic myeloid leukaemia; results of treatment. Lancet. 1953 Jan 31;264(6753):208–213. doi: 10.1016/s0140-6736(53)90885-x. [DOI] [PubMed] [Google Scholar]
  5. GURELI N., DENHAM S. W., ROOT S. W. Cytologic dysplasia related to busulfan (Myleran) therapy. Report of a case. Obstet Gynecol. 1963 Apr;21:466–470. [PubMed] [Google Scholar]
  6. HEARD B. E. Fibrous healing of old iatrogenic pulmonary edema ("hexamethonium lung"). J Pathol Bacteriol. 1962 Jan;83:159–164. doi: 10.1002/path.1700830119. [DOI] [PubMed] [Google Scholar]
  7. Harrold B. P. Syndrome resembling Addison's disease following prolonged treatment with busulphan. Br Med J. 1966 Feb 19;1(5485):463–464. doi: 10.1136/bmj.1.5485.463. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. KLAUS M., REISS O. K., TO OLEY W. H., PIEL C., CLEMENTS J. A. Alveolar epithelial cell mitochondria as source of the surface-active lung lining. Science. 1962 Sep 7;137(3532):750–751. doi: 10.1126/science.137.3532.750. [DOI] [PubMed] [Google Scholar]
  9. Koss L. G., Melamed M. R., Mayer K. The effect of busulfan on human epithelia. Am J Clin Pathol. 1965 Oct;44(4):385–397. doi: 10.1093/ajcp/44.4.385. [DOI] [PubMed] [Google Scholar]
  10. LEAKE E., SMITH W. G. DIFFUSE INTERSTITIAL PULMONARY FIBROSIS AFTER BUSULPHAN THERAPY. Lancet. 1963 Aug 31;2(7305):432–434. doi: 10.1016/s0140-6736(63)92173-1. [DOI] [PubMed] [Google Scholar]
  11. NELSON B. M., ANDREWS G. A. BREAST CANCER AND CYTOLOGIC DYSPLASIA IN MANY ORGANS AFTER BUSULFAN (MYLERAN). Am J Clin Pathol. 1964 Jul;42:37–44. doi: 10.1093/ajcp/42.1.37. [DOI] [PubMed] [Google Scholar]
  12. OLINER H., SCHWARTZ R., RUBIO F., DAMESHEK W. Interstitial pulmonary fibrosis following busulfan therapy. Am J Med. 1961 Jul;31:134–139. doi: 10.1016/0002-9343(61)90229-7. [DOI] [PubMed] [Google Scholar]
  13. SOLOMON C., LIGHT A. E., DE BEER E. J. Cataracts produced in rats by 1, 4-dimethanesulfonoxybutane (myleran). AMA Arch Ophthalmol. 1955 Dec;54(6):850–852. doi: 10.1001/archopht.1955.00930020856006. [DOI] [PubMed] [Google Scholar]
  14. Smalley R. V., Wall R. L. Two cases of busulfan toxicity. Ann Intern Med. 1966 Jan;64(1):154–164. doi: 10.7326/0003-4819-64-1-154. [DOI] [PubMed] [Google Scholar]
  15. WESTON J. T., GUIN G. H. Epithelial atypias with chemotherapy in 100 acute childhood leukemias. Cancer. 1955 Jan-Feb;8(1):179–186. doi: 10.1002/1097-0142(1955)8:1<179::aid-cncr2820080125>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  16. Ward H. N., Konikov N., Reinhard E. H. Cytologic dysplasia occurring after busulfan (Myleran) therapy. A syndrome resembling adrenocortical insufficiency and atrophic bronchitis. Ann Intern Med. 1965 Oct;63(4):654–660. doi: 10.7326/0003-4819-63-4-654. [DOI] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES